Vanguard Capital Management
TTRX

Vanguard Capital Management’s Turn Therapeutics TTRX Stock Holding History

Vanguard Capital Management’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Buy
74,301
+24,851
+50% +$115K ﹤0.01% 3703
2026
Q1 		$158K Buy
+49,450
New +$193K ﹤0.01% 3821

Other funds holding TTRX

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BA
Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Vanguard Capital Management's TTRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Turn Therapeutics (TTRX) stake by 50% in Q2 2026, buying an estimated $115K and bringing the position to 74,301 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #3703.

Vanguard Capital Management first reported a position in TTRX in Q1 2026 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

  • Vanguard Capital Management held 74,301 shares of Turn Therapeutics worth $542K as of Q2 2026.
  • Vanguard Capital Management bought 24,851 Turn Therapeutics shares in Q2 2026, an estimated $115K.
  • Turn Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3703 holding.
  • Vanguard Capital Management first reported a position in Turn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.